Trial Profile
Single nucleotide polymorphism and sunitinib treatment response in a cohort of metastatic renal cell carcinoma patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 30 Oct 2015 New trial record
- 27 Jun 2015 Results presented at 12th Congress of the European Association for Clinical Pharmacology and Therapeutics